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ABSTRACT
Objectives In most European countries, 
patients seeking medication abortion during 
the COVID-19 pandemic are still required 
to attend healthcare settings in person. We 
assessed whether demand for self- managed 
medication abortion provided by online 
telemedicine increased following the emergence 
of COVID-19.
Methods We examined 3915 requests for 
self- managed abortion to online telemedicine 
service Women on Web (WoW) between 1 
January 2019 and 1 June 2020. We used 
regression discontinuity to compare request 
rates in eight European countries before and 
after they implemented lockdown measures to 
slow COVID-19 transmission. We examined the 
prevalence of COVID-19 infection, the degree 
of government- provided economic support, the 
severity of lockdown travel restrictions and the 
medication abortion service provision model in 
countries with and without significant changes 
in requests.
Results Five countries showed significant 
increases in requests to WoW, ranging from 
28% in Northern Ireland (97 requests vs 75.8 
expected requests, p=0.001) to 139% in 
Portugal (34 requests vs 14.2 expected requests, 
p<0.001). Two countries showed no significant 
change in requests, and one country, Great 
Britain, showed an 88% decrease in requests 
(1 request vs 8.1 expected requests, p<0.001). 
Among countries with significant increases in 
requests, abortion services are provided mainly 
in person in hospitals or abortion is unavailable 
and international travel was prohibited 
during lockdown. By contrast, Great Britain 
implemented a fully remote no- test telemedicine 
service.
Conclusion These marked changes in requests 
for self- managed medication abortion during the 
COVID-19 pandemic demonstrate demand for 
remote models of care, which could be fulfilled 
by expanding access to medication abortion by 
telemedicine.
INTRODUCTION
The COVID-19 pandemic has posed chal-
lenges for the provision of abortion care in 
Europe. Reallocation of resources, rede-
ployment of staff and social distancing 
requirements introduced new barriers to 
in- person clinic visits.1 2
Countries differed in their policy 
responses to these new challenges. Great 
Britain authorised home use of mifepris-
tone, and by doing so, changed the service 
delivery model for medication abortion 
to a fully remote no- test telemedicine 
service. People accessing medication 
Key messages
 ► Following the emergence of COVID-19, 
demand for self- managed medication 
abortion increased in countries where 
abortion is provided mainly in hospitals 
and where travel restrictions were most 
stringent.
 ► By contrast, in Great Britain, the one 
country that implemented fully remote 
no- test medication abortion services, 
demand for self- managed abortion 
declined almost to zero.
 ► Findings demonstrate the urgent need 
for policymakers to expand access to 
medication abortion by telemedicine.
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abortion up to 10 weeks’ gestation were able to consult 
with a provider by phone and have mifepristone and 
misoprostol mailed for home use, with no ultrasound 
or in- person tests required.3–5 France extended the 
ability to take abortion medications at home following 
an in- person visit with a healthcare professional from 
7 weeks to 9 weeks of gestation.6 Germany allowed 
mandatory preabortion counselling to take place 
by phone or video teleconsult instead of in person.7 
Portugal waived the usual required waiting period 
and allowed follow- up to be postponed or done by 
telemedicine, but in- person visits were still required 
for service provision.8 Hungary, which provides only 
surgical abortions, suspended almost all services as a 
result of a government ban on non- life saving proce-
dures early in the pandemic.8 Overall, most European 
countries made few major changes to increase access 
to medication abortion and all but Great Britain 
continued to require at least one in- person visit to a 
provider, despite calls from human rights groups to 
prioritise patient safety and expand remote access.7 9
The economic downtown and rising unemploy-
ment across Europe in the wake of the pandemic may 
increase demand for abortion care at a time when it is 
even more difficult to access in the clinic setting. This 
situation raises the possibility of more abortions taking 
place outside the formal healthcare setting (ie, self- 
managed abortions). MSI Reproductive Choices esti-
mates that an additional 2.7 million unsafe abortions 
will take place globally as a result of health service 
disruptions caused by the pandemic.10
However, not all abortions that take place outside 
the formal healthcare settings are unsafe. Self- managed 
medication abortion provided through online telemed-
icine services has been shown to be a safe and effec-
tive option, although it is not without potential legal 
risks.11 12 Using data from one such service, we assessed 
whether demand for online telemedicine abortion 
changed in eight European countries after stay- at- 
home restrictions to slow the spread of COVID-19 
were introduced.
METHODS
We obtained fully deidentified data from Women on 
Web (WoW), a non- profit organisation that provides 
self- managed medication abortion by telemedicine up 
to 10 weeks’ gestation.13 The service is accessed via 
an online form, which directly populates the data-
base from which our data were obtained. Submitted 
forms are screened by a doctor and if clinical eligi-
bility criteria are met, mifepristone and misoprostol 
are sent by mail. In some countries, referrals are also 
made to local in- clinic services. A donation of €70–90 
is requested to support the service, but may be waived 
or reduced in cases of financial hardship. Information 
and support are provided via email in 16 languages by 
a trained helpdesk team. People accessing the service 
consent to the fully anonymised use of their data for 
research purposes when submitting the online consul-
tation form.
Our analytic sample includes eight countries: 
Germany, Hungary, Italy, Malta, the Netherlands, 
Northern Ireland, Portugal and Great Britain. WoW 
currently accepts online consultations from 20 coun-
tries in Europe. We excluded nine countries that had 
too few requests to reliably detect differences in request 
numbers between the ‘before’ and ‘after’ periods (ie, 
fewer than 10 expected requests in the ‘after’ period). 
We also excluded Spain because the Spanish govern-
ment censored the WoW website during the study 
period and so no requests could be made,14 Poland 
because the number of requests made to WoW has 
been unstable since the beginning of 2020 and France 
because consultations have only been accepted since 
January 2020, meaning there were too few to calculate 
a baseline trend in requests.
We obtained the daily number of requests made to 
WoW from the eight countries in our sample between 
1 January 2019 and 1 June 2020 (the last day on 
which lockdown measures were lifted in a country is 
included in the analysis). The location of each request 
was derived from country of residence information 
provided by the person making the request through 
the online consultation form. We excluded duplicate 
requests, which were identified as >1 request with the 
same information and location made within 12 hours. 
The number of requests from each country was anal-
ysed using a regression- discontinuity design where 
time is the running variable (also known as interrupted 
time series).15 We designated a ‘before’ period, which 
began on 1 January 2019 and ended on the date that 
each individual country’s government issued their 
first ‘stay- at- home’ directive. The one exception was 
Germany, where the ‘before’ period began on 1 January 
2020 because WoW did not accept consultations from 
Germany until late 2019. The ‘after’ period began the 
first day after the ‘stay- at- home’ directive was issued 
for each country and ended on the first day that the 
directives were eased in each country. ‘Stay- at- home’ 
directives were chosen as the threshold date defining 
the ‘pre’ and ‘post’ periods because the majority of 
European countries issued such a directive, which 
posed definitive limitations on population movement 
and activities. Of the countries included in our analytic 
sample, only Malta did not issue a population- wide 
directive and we instead used the date on which the 
Maltese government issued a directive to close public 
places.16
We fit a generalised linear model for each country’s 
daily requests between 1 January 2019 (1 January 
2020, for Germany) and the date of easing ‘stay- at- 
home’ restrictions. The model incorporated a dummy 
variable for the ‘before’ versus ‘after’ period, repre-
senting a possible discontinuity at the day of the ‘stay- 
at- home’ directive. The statistical significance of the 
discontinuity for each country was assessed using a 
Aiken ARA, et al. BMJ Sex Reprod Health 2021;0:1–8. doi:10.1136/bmjsrh-2020-200880 3
Original research
likelihood ratio test to compare with a null model 
that did not include a dummy variable for the ‘before’ 
versus ‘after’ period. The null model was also used to 
generate Monte Carlo simulations for each country, 
which create a probability distribution of the expected 
requests in the ‘after’ period with no discontinuity. 
The observed requests line would be highly likely to 
lie within this probability distribution if there was no 
difference in requests between the ‘before’ and ‘after’ 
periods. We also calculated the percentage differ-
ence between observed and expected requests in the 
‘after’ period as 100×(actual−expected)/expected 
and compared the null and regression discontinuity 
models via likelihood ratio tests. For Northern 
Ireland, both the null and discontinuity models also 
included a dummy variable indicating the period after 
10 April 2020, because abortion services were autho-
rised for the first time in Northern Ireland on this 
date.17
We also compiled information for each country 
on several metrics we hypothesised that could be 
related to demand for online abortion: stringency of 
‘stay- at- home’ requirements; deaths due to COVID-
19; economic assistance provided by governments18 
and abortion service provision before and during the 
pandemic.7 8 19–21 We examined each of these metrics 
Figure 1 Observed versus expected requests to Women on Web for all countries included in the analysis. Cumulative requests in the ‘before’ versus ‘after’ 
periods are in black and orange, respectively. Vertical dashed lines show the dates when stay- at- home orders were announced. The blue line shows the 
model without any discontinuities (the null model), and the green line shows the model fit with a discontinuity. for the stay- at- home order. The pink lines are 
the 250 Monte Carlo simulations from the null model, which support the likelihood ratio test’s finding that the model with discontinuities is a significantly 
better fit than the null model.
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across each country included in the analysis to assess 
their relationship to changes in requests to WoW.
Data analysis was conducted using the R statistical 
package V.3.6.2.22 Findings were considered statisti-
cally significant at an alpha level of 0.05. The study 
was reviewed by the Institutional Review Board at 
The University of Texas at Austin and was considered 
exempt on the basis that the study is an analysis of 
precollected, fully deidentified data.
Patient and public involvement
No patients were involved in the design or conduct of 
the study.
RESULTS
During the data collection period, WoW received 
3915 requests for abortion medications from the eight 
countries included in the analysis. Among these, we 
observed a statistically significant increase in requests 
during the ‘after’ period in five countries: Hungary, 
Italy, Malta, Portugal and Northern Ireland (figure 1). 
The magnitude of the observed increases ranged from 
139% above expected in Portugal to 28% above 
expected in Northern Ireland (table 1). In two countries 
(Germany, the Netherlands), there was no statistically 
significant difference in observed numbers compared 
with expected numbers of requests in the ‘after’ period 
(figure 1 and table 1). In one country (Great Britain), 
there was a statistically significant decrease in requests 
in the ‘after’ period (figure 1 and table 1).
Countries which had higher numbers of COVID-
19- related deaths or which provided less government 
economic support during the pandemic did not appear 
to have higher numbers of requests to WoW (table 2). 
We did, however, observe a relationship between 
higher numbers of requests and both the location of 
abortion service provision and the severity of domestic 
and international travel restrictions (table 2). In Italy, 
Portugal and Hungary, all of which showed significant 
increases in requests to WoW, abortion is provided 
mostly in the hospital setting and all enacted stringent 
stay- at- home requirements. In Northern Ireland and 
Malta, where significant increases in requests were 
also observed, in- clinic abortion services are only avail-
able by travelling outside of the country, and interna-
tional travel was restricted during the study periods. 
In Germany and the Netherlands, we observed no 
increases in requests, abortion services remained avail-
able in clinic settings and no countrywide domestic 
travel restrictions were enacted. In Great Britain, 
abortion services were made available by fully remote 
telemedicine shortly after lockdown began and we 
observed a significant decrease in requests.
DISCUSSION
During the first wave of the COVID-19 pandemic in 
Europe, we observed changes in requests to the WoW 
online telemedicine abortion service among five out 
of eight countries in our analysis. Among countries 
where abortion is legally available within the formal 
healthcare setting, we observed increased requests in 
those countries that had more stringent stay- at- home 
requirements—including countrywide domestic travel 
restrictions—and where abortion is mostly available 
only in the hospital setting. Among the two countries 
where abortion was not legally available within the 
formal healthcare setting during the study period and 
where travel outside the country was restricted, we 
also observed an increase in requests. Among countries 
where abortion is legally available but which enacted 
less stringent stay- at- home policies (including no coun-
trywide domestic travel restrictions) and where abor-
tions are provided outside the hospital setting, we 
observed no increases in requests. In the sole country 
where abortion services were made available by fully 
remote telemedicine during the study period, we 
observed a significant decrease in requests.
Our data provide a unique window into requests 
for self- managed medication abortion using online 
telemedicine during the COVID-19 pandemic. Key 
strengths include the ability to measure changes in 
demand for self- managed abortion without relying 
on self- reporting and the ability to compare data 
Table 1 Actual versus expected numbers of self- managed abortion requests in the ‘after’ period for each country included in the study











Portugal 11 34 14.2 139.0 (54.5 to 385.7) <0.001
Italy 603 53 31.6 67.9 (23.3 to 152.4) <0.001
Hungary 279 113 83.2 35.8 (11.9 to 71.2) <0.001
Malta 162 69 52.3 31.9 (3.0 to 76.9) <0.001
Northern Ireland (UK) 984 97 75.8 28.0 (4.3 to 64.4) 0.001
Germany 620 465 467.1 −0.5 (−9.0 to 9.2) 0.798
The Netherlands 317 47 50.9 −7.7 (−28.8 to 27.0) 0.458
Great Britain 60 1 8.1 −87.6(–92.9 to –66.7) <0.001
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from before and after the emergence of COVID-19. 
An important limitation, however, is that there are 
other pathways to abortion outside the formal health-
care setting in Europe, including alternative sources 
of mifepristone and misoprostol and non- medication 
methods, such as botanicals. Thus, we cannot measure 
all demands for self- managed abortion during the 
pandemic. In addition, the quasi- experimental design 
of our study lends itself to examining associations 
rather than formally establishing causal links. We 
also lack nuanced insight into the reasons underlying 
changes in requests to WoW for any particular country. 
In the two countries where we observed no increases 
in requests, people likely still encountered challenges 
to accessing abortion.23 Future qualitative work could 
address this knowledge gap, as well as explore people’s 
preferences for how and where to access abortion care.
Our results may reflect two distinct phenomena. 
First, in some countries, more people may be seeking 
abortion through all available channels during the 
pandemic. The decision to end a pregnancy could 
be due to the perception of risk posed by COVID-
19, reduced access to prenatal care or limited social 
support during lockdowns.24 Additionally, decision- 
making could be influenced by the economic downturn 
COVID-19 has precipitated.25 Social distancing poli-
cies may also increase rates of unintended pregnancy 
due to increased time spent at home with a partner or 
reduced access to contraception.26
Second, the observed increases in requests may 
represent a shift in demand from in- clinic abortion 
to self- managed abortion using online telemedicine. 
In countries where abortion services are provided 
predominantly or solely in hospital settings, people 
may have feared entering a hospital due to perceived 
or real risk of infection. Even where limited alterna-
tives are available in the community setting, accessing 
these services may still have been extremely chal-
lenging due to the infection risk associated with 
public transport, inability to escape surveillance from 
a controlling partner or difficulty finding childcare. 
Moreover, in countries with no abortion services, the 
inability to travel abroad to seek abortion care due to 
travel restrictions may have led more people to seek 
an alternative in online telemedicine. Indeed, our find-
ings from Northern Ireland show a steep increase in 
requests to WoW following the introduction of lock-
down measures, followed by a levelling off shortly 
after the introduction of within- country abortion 
services. We do not necessarily interpret this pattern as 
an indication of the immediate availability of abortion 
services in Northern Ireland, since people living there 
may have been responding to the authorisation of 
services only to find that nothing had yet become avail-
able or that new services were very limited in scope. 
Additionally, BPAS made a pills by post service avail-
able in Northern Ireland, which could also account for 
some of the decline in requests to WoW.
People in countries where the challenges to accessing 
medication abortion are greatest found their own solu-
tions outside the clinic setting during the COVID-19 
pandemic. However, while self- managed medication 
abortion provided via online telemedicine is a safe and 
effective option,11 12 it is not without legal risks.27 Its 
safety also depends on access to the formal healthcare 
system when necessary, which is not guaranteed during 
a pandemic. Additionally, while some people may 
prefer self- managed medication abortion, others may 
experience it as fraught and isolating due to stigma or 
the threat of criminalisation and may prefer in- clinic 
care.28 Despite the fact that the WHO recommends 
the use of telemedicine abortion provision models 
during the COVID-19 pandemic,29 only Great Britain 
responded to pandemic by purposefully changing their 
medication abortion service to circumvent the difficul-
ties of in- person care. Following the introduction of 
a fully remote no- test telemedicine service for medi-
cation abortion up to 10 weeks’ gestation, requests to 
WoW decreased to a single consultation. This dramatic 
decrease points not only to the removal of access 
barriers posed by COVID-19, but also of pre- existing 
barriers. Evidence from other settings suggests that 
similar telemedicine models for medication abortion 
are safe, effective and acceptable to patients.30
CONCLUSION
Our findings provide evidence in support of the need 
for service model changes to make medication abor-
tion more accessible during and beyond the COVID-19 
pandemic. Fully remote no- test provision of early 
medication abortion negates the need to visit a hospital 
or healthcare facility, thus preserving personal protec-
tive equipment and reducing infection risks for both 
patients and healthcare providers. Follow- up care can 
be provided in the clinic if necessary, and patients have 
clear continuity of care in the rare instances in which 
adverse events occur. Authorising and implementing 
telemedicine models within the formal healthcare 
setting in line with the WHO recommendations would 
help to meet the demand we observed for remote 
provision and would ensure truly patient- centred care.
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